Dr. Mikhail Kosiborod, cardiologist and vice president of research at Saint Luke's Health System, joined Medscape InDiscussion to talk about the cardiovascular effects of type 2 diabetes medications.

"As a cardiologist who has been interested in this for so long, I'm looking at the most promising developments for new medications for treating cardiovascular disease, both atherosclerotic cardiovascular disease (ASCVD) and heart failure," Kosiborod said. "And the most promising developments are coming from the field of metabolism."

Listen to or read the Medscape InDiscussion episode: A Brave New World in Type 2 Diabetes Treatment and Beyond